Compass Therapeutics to Participate in Upcoming June Investor Events
Rhea-AI Summary
Compass Therapeutics (Nasdaq:CMPX) will participate in two June 2026 investor conferences focused on healthcare.
Management will present at the Jefferies Global Healthcare Conference on June 4 at 8:45 AM ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 8:00 AM ET, with webcasts and replays available.
Positive
- None.
Negative
- None.
News Market Reaction – CMPX
In the May 28 session, CMPX gained 6.17%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Phase 1 data update | Positive | +7.3% | Promising CTX-8371 Phase 1 responses with 33% ORR at higher doses. |
| May 12 | Investor conferences | Neutral | +2.2% | Participation in May biotechnology and oncology investor conferences with webcasts. |
| May 05 | Q1 2026 earnings | Positive | +0.5% | Q1 results plus positive tovecimig data and cash of $195M with runway into 2028. |
| Apr 27 | Phase 2/3 results | Positive | -64.4% | COMPANION-002 showed improved PFS and ORR for tovecimig plus paclitaxel. |
| Apr 24 | Topline webcast alert | Neutral | -64.4% | Announcement of upcoming webcast to review COMPANION-002 topline secondary endpoints. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News on clinical progress and corporate updates has often led to positive moves, but some major trial readouts coincided with sharp declines, indicating inconsistent market reactions to ostensibly positive data.
Over the past months, Compass reported key clinical and corporate milestones. Positive Phase 2/3 data for tovecimig in biliary tract cancer and subsequent detailed COMPANION-002 results were accompanied by large negative moves of about -64.41%. By contrast, the May 2026 earnings update with a net loss of $18.3M but a cash runway into 2028, plus ASCO Phase 1 data for CTX-8371 and prior investor-event announcements, saw modest gains between roughly 0.52% and 7.25%. Today’s June conference participation fits the pattern of routine investor-engagement news.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of June.
Details are as follows:
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Time: 8:45 AM ET
Webcast Link: https://cmpx.info/jefferies
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Time: 8:00 AM ET
Webcast Link: https://cmpx.info/gs
Virtual/Replay availability: Presentations will be archived on Compass’ Events page.
Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
About Compass Therapeutics
Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visit www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
